Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 16.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 63,602 shares of the company’s stock after selling 12,657 shares during the quarter. Eagle Asset Management Inc.’s holdings in Krystal Biotech were worth $12,696,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. HealthInvest Partners AB lifted its position in Krystal Biotech by 20.7% during the 3rd quarter. HealthInvest Partners AB now owns 9,202 shares of the company’s stock worth $1,675,000 after acquiring an additional 1,578 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Krystal Biotech by 9.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock worth $43,727,000 after purchasing an additional 19,777 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Krystal Biotech during the third quarter worth $1,323,000. Segall Bryant & Hamill LLC grew its position in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after buying an additional 122,407 shares during the last quarter. Finally, Quest Partners LLC increased its stake in Krystal Biotech by 264.1% in the 3rd quarter. Quest Partners LLC now owns 1,398 shares of the company’s stock valued at $254,000 after buying an additional 1,014 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

KRYS opened at $190.40 on Friday. The company has a market cap of $5.48 billion, a price-to-earnings ratio of 107.57 and a beta of 0.82. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The business’s fifty day moving average is $179.54 and its two-hundred day moving average is $182.23.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the previous year, the firm earned ($0.67) EPS. The business’s revenue for the quarter was up 879.9% compared to the same quarter last year. On average, analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $202.29.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).